Therini Bio’s Series A Financing Round for Targeted Therapies
Therini Bio, a biopharmaceutical company dedicated to developing targeted therapies for neurodegenerative and eye disorders, has recently closed a Series A financing round of $36 million. T
his includes investment from the Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, and Impact Medicine Fund. The funding will be used to further advance their lead candidate drug, THN391, which aims to selectively target fibrin in order to tackle the root causes of neurodegeneration and eye disorders.
Fibrin is a protein involved in blood clotting but also plays a role in disease progression. In this post, we’ll explore the need for targeted therapies in these diseases, how THN391 works, and the recent financing round and future plans for Therini.
The Need for Targeted Therapies in Neurodegeneration and Eye Disorders
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s, and eye disorders such as macular degeneration, affect millions of people worldwide.
At present, treatments for these diseases concentrate on alleviating symptoms but frequently result in notable side effects and do not address the fundamental cause of the ailment. The limited efficacy of current treatments highlights the need for more targeted therapies.
While fibrin is primarily responsible for blood coagulation, it also contributes to the advancement of neurodegenerative conditions and eye ailments. Fibrin accumulates in the brain and eye tissues in these diseases, contributing to inflammation and tissue damage.
Increasingly, there is mounting evidence that implicates fibrin in the advancement of multiple sclerosis, Alzheimer’s, and retinal ailments. This leads to the conclusion that targeting fibrin could potentially have significant therapeutic benefits.
THN391: An Innovative Approach to Blocking Fibrin
THN391 is a small molecule drug developed by Therini Bio that selectively targets fibrin without affecting its clotting properties.
The drug binds specifically to a site on fibrin that plays a crucial role in disease progression while leaving the clotting properties of fibrin intact. In preclinical trials, THN391 has been shown to reduce the hallmarks of multiple sclerosis, Alzheimer’s, and retinal diseases.
One of the significant advantages of THN391 is that it can cross the blood-brain barrier, which is critical for the treatment of neurological diseases. The blood-brain barrier is a selectively permeable membrane that protects the brain from harmful substances in the blood.
However, this also presents a challenge for the delivery of therapeutics to the brain. THN391 has shown the ability to cross the blood-brain barrier, which is a significant accomplishment.
Series A Financing Round
Therini Bio recently closed a Series A financing round of $36 million, which includes investment from the Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, and Impact Medicine Fund.
This funding will be used to advance the clinical development of THN391 and further the company’s research into neurodegeneration and eye disorders simultaneously. The round of funding is a testament to the promise of THN391 and Therini’s innovative approach to developing targeted therapies.
Milestones and Future Plans
Therini Bio has made significant progress since its inception, including previous funding rounds. With the recent investments, Therini will be able to advance the clinical development of THN391 and achieve critical milestones.
The company aims to further validate the effectiveness of THN391 in reducing hallmarks of neurodegeneration and eye disorders in preclinical and clinical trials. Ultimately, Therini hopes to help patients with neurodegeneration and eye disorders by developing targeted therapies that address the root cause of their condition.
The Future of Neurodegenerative and Eye Disorder Treatment
Neurodegenerative and eye disorders are highly prevalent, affecting millions of individuals worldwide. Yet, current treatments often have significant limitations, highlighting the need for more targeted therapies.
Therini Bio and its drug, THN391, represents a promising new approach to tackling the root causes of these diseases through targeted therapy. With significant investments and promising preclinical trials,
Therini is well-positioned to achieve milestones and make significant strides in the development of targeted therapies for neurodegenerative and eye disorders. We look forward to following Therini’s progress and its potential impact on patient’s lives.